No Data
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
Buy Rating Affirmed for VYNE Therapeutics Amid Promising Early Data for VYN202
Express News | Vyne Therapeutics Inc: Vyn202 Was Generally Well Tolerated With No Drug-Related Adverse Events
Express News | Vyne Therapeutics Inc: Positive Phase 1a Sad Data for Vyn202, a Novel BD2-Selective Bet Inhibitor
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
Tarabut Acquires UK Payments Platform Vyne Ahead of New MENA Regulatory Requirements
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
